Dr. Bielamowicz joined the faculty at UAMS/Arkansas Children's Hospital in 2016. He received his undergraduate degree in Biology and Education from the University of Texas at Austin. He then attended medical school at the University of Texas Southwestern Medical Center in Dallas.

He completed a pediatric residency at UAMS/Arkansas Children's Hospital followed by a fellowship in pediatric hematology and oncology at Baylor College of Medicine/Texas Children's Hospital. He also completed a neuro-oncology fellowship at Baylor College of Medicine/Texas Children's Hospital.

Dr. Bielamowicz is an Assistant Professor in the section of Pediatric Hematology and Oncology and holds dual board certification in pediatrics and pediatric hematology/oncology. He serves as the medical director of the Brain Tumor Clinic at Arkansas Children's and the Innovative Cancer Therapeutics Program at Arkansas Children's.  His areas of clinical focus and research interests include pediatric brain and spinal cord tumors, early phase clinical trials, histiocytic disorders, neuroblastoma, retinoblastoma, and genetic cancer predisposition syndromes.

Dr. Kevin Bielamowicz received his undergraduate degree in Biology and Education from the University of Texas at Austin. He then attended medical school at the University of Texas Southwestern Medical Center in Dallas.  He completed a pediatric residency at UAMS/Arkansas Children's Hospital followed by a fellowship in pediatric hematology and oncology at Baylor College of Medicine/Texas Children's Hospital. He also completed a neuro-oncology fellowship at Baylor College of Medicine/Texas Children's Hospital.


Dr. Bielamowicz joined the faculty at UAMS/Arkansas Children’s Hospital in 2016.  He is an Assistant Professor in the section of Pediatric Hematology and Oncology and holds dual board certification in pediatrics and pediatric hematology/oncology. He serves as the medical director of the Brain Tumor Clinic at Arkansas Children’s.

His clinical and research interests include pediatric brain and spinal cord tumors and histiocytic diseases.  He is a member of the experimental therapeutics team at ACH and is involved in clinical trial design and implementation through several national and international consortia including the Children's Oncology Group, Beat Childhood Cancer Consortium, Pediatric Oncology Experimental Therapeutics Investigators Consortium (POETIC), the Southern Neuro-Oncology Consortium (SoPNOC), NEXT Consortium, and the North American Consortium for Histiocytosis (NACHO).  He aims to provide children of Arkansas with cancers that do not have curative therapy at diagnosis or are refractory to standard therapy to have novel treatment options here at home.  Clinical trials for these patients at Arkansas Children's Hospital include strategies such as immunotherapy, precision medicine, bone marrow transplantations, and experimental therapeutics.